nach oben

Neurological Sciences

Erschienen in:

01.08.2011 | Review Article

Temporal lobe epilepsy and anti glutamic acid decarboxylase autoimmunity

verfasst von: Luca Errichiello, Salvatore Striano, Federico Zara, Pasquale Striano

Erschienen in: Neurological Sciences | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Epilepsy is one of the most impactful diseases on social life. A significant number of epileptic syndromes have been linked to immunological alterations. Elevated levels of antibodies against glutamic acid decarboxylase have been recently found in a significant percentage of patients with temporal lobe epilepsy, the most common epilepsy type. The clinical and pathogenetic relationship of this association is discussed. This link may have important therapeutic implications and merits additional clinical and laboratory research.

Cascino GD (2008) When drugs and surgery don’t work. Epilepsia 49(Suppl 9):79–84PubMedCrossRef

Sander JW (2003) The epidemiology of epilepsy revisited. Curr Opin Neurol 16(2):165–170PubMedCrossRef

Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B, Cavalcanti D, Baulac M (1998) Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 51(5):1256–1262PubMed

Kwan P, Brodie MJ (2003) Clinical trials of antiepileptic medications in newly diagnosed patient with epilepsy. Neurology 60(11 Suppl 4):S2–S12PubMed

Billiau AD, Wouters CH, Lagae LG (2005) Epilepsy and the immune system: is there a link? Eur J Paediatr Neurol 9(1):29–42PubMedCrossRef

Bernasconi P, Cipelletti B, Passerini L, Granata T, Antozzi C, Mantegazza R, Spreafico R (2002) Similar binding to glutamate receptors by Rasmussen and partial epilepsy patients’ sera. Neurology 59(12):1998–2001PubMed

van Engelen BG, Renier WO, Weemaes CM, Gabreels FJ, Meinardi H (1994) Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Res 19(3):181–190PubMedCrossRef

Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, Ramió-Torrentà L, Graus F (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 131(Pt 10):2553–2563PubMedCrossRef

Peltola J, Kulmala P, Isojärvi J, Saiz A, Latvala K, Palmio J, Savola K, Knip M, Keränen T, Graus F (2000) Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 55(1):46–50PubMed

10.

Giometto B, Nicolao P, Macucci M, Tavolato B, Foxon R, Bottazzo GF (1998) Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. Lancet 352:457PubMedCrossRef

11.

Errichiello L, Perruolo G, Pascarella A, Formisano P, Minetti C, Striano S, Zara F, Striano P (2009) Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: a study on 233 patients. J Neuroimmunol 211(1–2):120–123PubMedCrossRef

12.

Liimatainen S, Peltola M, Sabater L, Fallah M, Kharazmi E, Haapala AM, Dastidar P, Knip M, Saiz A, Peltola J (2010) Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 51(5):760–767PubMed

13.

Sokol DK, McIntyre JA, Wagenknecht DR, Dropcho EJ, Patel H, Salanova V, da Costa G (2004) Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy. Neurology 62(3):517–518PubMed

14.

Irani SR, Bien CG, Lang B (2011) Autoimmune epilepsies. Curr Opin Neurol 24(2):146–153PubMedCrossRef

15.

Faulkner-Jones BE, Cram DS, Kun J, Harrison LC (1993) Localization and quantitation of expression of two glutamate decarboxylase genes in pancreatic beta-cells and other peripheral tissues of mouse and rat. Endocrinology 133(6):2962–2972PubMedCrossRef

16.

Bu DF, Tobin AJ (1994) The exon-intron organization of the genes encoding two human glutamate decarboxylases (GAD65 and GAD 67) suggests that they derive from a common ancestral GAD. Genomics 21:222–228PubMedCrossRef

17.

Asada H, Kawamura Y, Maruyama K, Kume H, Ding RG, Kanbara N, Kuzume H, Sanbo M, Yagi T, Obata K (1997) Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA 94(12):6496–6499PubMedCrossRef

18.

Hong J, Heng W, Gregory O, Jianning W, Kathleen D, Di S, Eric F, Che-Chang H, Richard DK, Jang-Yen W (2003) Demonstration of functional coupling between gamma -aminobutyric acid (GABA) synthesis and vesicular GABA transport into synaptic vesicles. PNAS 100:4293–4298

19.

Kash SF, Johnson RS, Tecott LH, Noebels JL, Mayfield RD, Hanahan D, Baekkeskov S (1997) Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA 94(25):14060–14065PubMedCrossRef

20.

Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P (1990) Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322:1555–1560PubMedCrossRef

21.

Espay AJ, Chen R (2006) Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome. Muscle Nerve 34(6):677–690PubMedCrossRef

22.

Dalakas MC, Fujii M, Li M, McElroy B (2000) The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 55:1531–1535PubMed

23.

Sperber EF, Velísková J, Germano IM, Friedman LK, Moshé SL (1999) Age-dependent vulnerability to seizures. Adv Neurol 79:161–169PubMed

24.

Lloyd KG, Scatton B, Voltz C, Bryere P, Valin A, Naquet R (1986) Cerebrospinal fluid amino acid and monoamine metabolite levels of Papio papio: correlation with photosensitivity. Brain Res 363(2):390–394PubMedCrossRef

25.

Esclapez M, Trottier S (1989) Changes in GABA-immunoreactive cell density during motor focal epilepsy induced by cobalt in the rat. Exp Brain Res 76(2):369–385PubMedCrossRef

26.

Fritsch B, Qashu F, Figueiredo TH, Aroniadou-Anderjaska V, Rogawski MA, Braga MF (2009) Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis. Neuroscience 163(1):415–429PubMedCrossRef

27.

Treiman DM (2001) GABAergic mechanisms in epilepsy. Epilepsia 42(Suppl 3):8–12PubMedCrossRef

28.

Macdonald RL, Kelly KM (1995) Antiepileptic drug mechanisms of action. Epilepsia 36(Suppl 2):S2–S12PubMedCrossRef

29.

Vianello M, Tavolato B, Giometto B (2002) Glutamic acid decarboxylase autoantibodies and neurological disorders. Neurol Sci 23:145–151PubMedCrossRef

30.

Aykutlu E, Baykan B, Gürses C, Gokyigit A, Saruhan-Direskeneli G (2005) No association of anti-GM1 and anti-GAD antibodies with juvenile myoclonic epilepsy: a pilot study. Seizure 14(5):362–366PubMedCrossRef

31.

Striano P, Perruolo G, Errichiello L, Formisano P, Beguinot F, Zara F, Striano S (2008) Glutamic acid decarboxylase antibodies in idiopathic generalized epilepsy and type 1 diabetes. Ann Neurol 63:127–128PubMedCrossRef

32.

Striano P, Errichiello L, Striano S (2011) Autoantibodies to glutamic acid decarboxylase in patients with epilepsy: what is their clinical relevance? Epilepsy Behav 20:145PubMed

33.

Levy LM, Levy-Reis I, Fujii M, Dalakas MC (2005) Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 62(6):970–974PubMedCrossRef

34.

Fishman PS, Drachman DB (1995) Internalization of IgG in motoneurons of patients with ALS: selective or nonselective? Neurology 45(8):1551–1554PubMed

35.

Vianello M, Bisson G, Dal Maschio M, Vassanelli S, Girardi S, Mucignat C, Fountzoulas K, Giometto B (2008) Increased spontaneous activity of a network of hippocampal neurons in culture caused by suppression of inhibitory potentials mediated by anti-gad antibodies. Autoimmunity 41(1):66–73PubMedCrossRef

36.

Vianello M, Keir G, Giometto B, Betterle C, Tavolato B, Thompson EJ (2005) Antigenic differences between neurological and diabetic patients with anti-glutamic acid decarboxylase antibodies. Eur J Neurol 12:294–299PubMedCrossRef

37.

Vianello M, Giometto B, Vassanelli S, Canato M, Betterle C, Mucignat C (2006) Peculiar labeling of cultured hippocampal neurons by different sera harbouring anti-glutamic acid decarboxylase autoantibodies (GAD-Ab). Exp Neurol 202:514–518PubMedCrossRef

38.

Kanter IC, Huttner HB, Staykov D, Biermann T, Struffert T, Kerling F, Hilz MJ, Schellinger PD, Schwab S, Bardutzky J (2008) Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia 49(5):914–920PubMedCrossRef

39.

Matà S, Muscas GC, Naldi I, Rosati E, Paladini S, Cruciatti B, Bisulli F, Paganini M, Mazzi G, Sorbi S, Tinuper P (2008) Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol 199(1–2):155–159PubMedCrossRef

Titel: Temporal lobe epilepsy and anti glutamic acid decarboxylase autoimmunity
verfasst von: Luca Errichiello
Salvatore Striano
Federico Zara
Pasquale Striano
Publikationsdatum: 01.08.2011
Verlag: Springer Milan
Erschienen in: Neurological Sciences / Ausgabe 4/2011
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-011-0566-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Effects of heating coagulation of middle meningeal artery on plasma CGRP level and c-fos expression in migraine rat triggered by nitroglycerin

Fluctuating frontal lobe dysfunction in a patient with moyamoya disease

A study of six point mutation analysis of LRRK2 gene in Chinese mainland patients with Parkinson’s disease

Ingestion of gasoline in a suicide attempt: an uncommon cause of bilateral basal ganglia T1 hyperintensities

Atlas of the Epilepsies